---
title: Antivirals
author: J. Austin Straley, DO
layout: post
chapter: 9
section: 01
lesson: 18
date: 2023-03-30
---

- HAART when CD4+ \<350-500 or Viral Load ≥ 55K
  - 2+1 Therapy (NRTI + Protease Inhibitor or NNRTI)
- Pre-Exposure Prophylaxis (PrEP): Tenofovir Disoproxil and Emtricitabine
- Post-Exposure Prophylaxis (PEP): AZT, Lamivudine and nelfinavir for 4 weeks
  - Emtricitabine + Tenofovir Disoproxil + (Darunavir or Dolutegravir)
- Pregnant
  - Efavirenz and TDF
- Nucleoside RTIs (NRTIs)
  - MOA: Inhibits HIV DNA synthesis from RNA template by terminating DNA chain elongation
    - Competitive nucleoside/tide RT inhibitor
  - Abacavir (ABC)
    - SE: Lethal if HLA-B5701, test them, SJS
  - Emtricitabine (FTC)
  - Lamivudine (3TC)
    - HBV activity but different dosing
    - Minimal toxicity
  - Stavudine (d4T) and Didanosine (ddl)
    - SE: Peripheral neuropathy and Pancreatitis
  - Tenofovir Disoproxil Fumerate (TDF)
    - HBV activity
    - SE: Nausea, Fanconi syndrome, Renal insufficiency, tubular nephrotoxicity, Osteoporosis
      - Get DEXA in Men ≥50, Post-menopausal, RF
  - Tenofovir Alafenamide (TAF)
    - Better than TDF
    - SE: Nausea, More weight gain, Less Renal insufficiency, Osteoporosis
      - Get DEXA in Men ≥50, Post-menopausal, RF
  - Zidovudine (AZT)
    - SE: Nausea, headache, anemia and Granulocytopenia, lactic acidosis, lipodystrophy, myopathy
- Nonnucleoside RTIs (NNRTIs)
  - MOA: Inhibits HIV DNA synthesis from RNA template by terminating DNA chain elongation
    - Allosteric RT Inhibitor
  - Nevirapine
    - Hypersensitivity, rash, hepatitis
  - Ertavirine
  - Efavirenz
    - SE: Sleep, confused, psychotic, vivid dreams, rash, dyslipidemia
  - Rilpivirine
    - CI: PPIs (needs food and gastric acid for absorption)
  - Doravirine
- Protease Inhibitors
  - MOA: Inhibits HIV polyprotein cleavage
    - General: Hyperlipidemia, Hyperglycemia
  - Atazanavir
  - Darunavir
  - Lopinavir
  - Indinavir
    - SE: Nephrolithiasis, hyperbilirubinemia
- Integrase Inhibitors
  - MOA: Inhibits HIV DNA integration into host genome
  - Dolutegravir
  - Elvitegravir
  - Bictegravir
  - Raltegravir
- Fusion Inhibitors
  - MOA: Inhibits HIV fusion with target cell membrane by binding to HIV gp41
  - Enfuvirtide
- CCR5 Antagonist
  - MOA: Inhibits HIV entry by allosteric blocking of HIV gp120 interaction with CCR5 (tropism testing required)
  - Maraviroc
- Pharmacokinetic Boosters
  - Ritonavir
    - Low dose added to boost other Protease Inhibitor drug level
      - (Darunavir or Dolutegravir)
  - Cobicistat